Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03349372
Other study ID # CRC_GHN_2017_007
Secondary ID
Status Completed
Phase N/A
First received November 17, 2017
Last updated November 17, 2017
Start date November 1, 2016
Est. completion date October 31, 2017

Study information

Verified date November 2017
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Allogeneic hematopoietic stem cell transplantation is the only possible treatment for many malignant and non-malignant hemopathies. The graft-versus-host immunological reaction (GvH) is a frequent and sometimes serious complication. The objective is to study whether a systematic and early follow-up by a lung specialist of allografted patients would allow an earlier diagnosis of GvH with pulmonary complications.


Recruitment information / eligibility

Status Completed
Enrollment 227
Est. completion date October 31, 2017
Est. primary completion date October 31, 2017
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- 18 years of age or older

- patients with a hematopoietic stem cell transplantation

Exclusion Criteria:

- Death within 100 days post-surgery

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Hematopoietic stem cell transplantation
Hematopoietic stem cell transplantation

Locations

Country Name City State
France Croix-Rousse Hospital, Hospices Civils de Lyon Lyon

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Medical complications 100 days after allograft Medical complications, especially Graft-versus-Host reaction with pulmonary complications occurring within 100 days post-surgery are studied
See also
  Status Clinical Trial Phase
Completed NCT03483194 - Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH) Phase 2/Phase 3
Recruiting NCT03735992 - Mind-body Medicine for Patients With Malignant Hematological Diseases N/A
Recruiting NCT04959175 - Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies Phase 1/Phase 2
Withdrawn NCT04275154 - Immunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing CAR-T Cell Therapy
Terminated NCT00957580 - Trial of Pimasertib in Hematological Malignancies Phase 2
Completed NCT00997386 - Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States Phase 2
Completed NCT00389428 - Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer. Phase 1
Completed NCT02193880 - Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT) N/A
Recruiting NCT00071045 - Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
Not yet recruiting NCT05054231 - Immunological Profile for Patients Treated With CAR-T Cells N/A
Completed NCT02650791 - Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study Phase 3
Completed NCT01362179 - National Marrow Donor Program Long-Term Donor Follow-Up
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Terminated NCT03648372 - A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System Phase 1/Phase 2
Recruiting NCT03320915 - Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT Phase 2
Recruiting NCT06422533 - Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients N/A
Terminated NCT02895529 - A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy Phase 4
Active, not recruiting NCT03680092 - Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation Phase 2
Recruiting NCT03083327 - Prophylactic Early PN in HPT/BMT N/A
Recruiting NCT03743480 - Early Palliative Care and Hematological Cancer Patients N/A